XML 58 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Agreements - Lily (Details)
1 Months Ended 3 Months Ended 12 Months Ended 55 Months Ended 66 Months Ended
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Aug. 31, 2013
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Dec. 31, 2011
USD ($)
item
Jun. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Dec. 31, 2006
USD ($)
Collaborative Agreements disclosures                                    
Amount of arrangement consideration included in license and milestone fees       $ 76,000 $ 10,077,000 $ 10,692,000 $ 6,070,000 $ 5,086,000 $ 5,078,000 $ 41,417,000 $ 6,234,000 $ 26,915,000 $ 57,815,000 $ 39,455,000        
Costs related to the research and development services       38,652,000 $ 36,094,000 $ 38,199,000 $ 35,132,000 $ 30,437,000 $ 25,666,000 $ 27,647,000 $ 28,018,000 148,077,000 111,768,000 106,958,000        
Development and Commercialization License | Development milestones                                    
Collaborative Agreements disclosures                                    
Potential milestone payments                                   $ 4,500,000
Lilly                                    
Collaborative Agreements disclosures                                    
Payments received under collaboration agreement                               $ 28,200,000    
Costs related to the research and development services                       182,000 499,000 1,200,000        
Costs related to clinical materials sold                       1,100,000 1,100,000 $ 26,000        
Lilly | Right-to-test agreement                                    
Collaborative Agreements disclosures                                    
Number of development and commercialization licenses taken | item                             3      
Payments received under collaboration agreement                             $ 20,000,000      
License exercise fee, per license                             2,000,000      
Lilly | Development and Commercialization License                                    
Collaborative Agreements disclosures                                    
Payments received under collaboration agreement $ 2,000,000 $ 2,000,000                             $ 23,500,000  
Potential milestone payments                             $ 199,000,000      
Estimated utilization period after commercialization                             10 years      
Discount rate (as a percent)                             16.00%      
Amount of arrangement consideration included in license and milestone fees     $ 7,800,000                   $ 15,600,000          
Estimated term of development and commercialization license                             25 years      
Lilly | Development and Commercialization License | Phase I clinical trial                                    
Collaborative Agreements disclosures                                    
Potential milestone payments       5,000,000               5,000,000       5,000,000 5,000,000  
Amount of arrangement consideration included in license and milestone fees                       5,000,000            
Lilly | Development and Commercialization License | Phase II clinical trial                                    
Collaborative Agreements disclosures                                    
Potential milestone payments       $ 9,000,000               $ 9,000,000       $ 9,000,000 9,000,000  
Lilly | Development and Commercialization License | Future Technological Improvements                                    
Collaborative Agreements disclosures                                    
Payments received under collaboration agreement                                 600,000  
Lilly | Development and Commercialization License | Research Services                                    
Collaborative Agreements disclosures                                    
Payments received under collaboration agreement                                 3,300,000  
Lilly | Development and Commercialization License | Regulatory milestones                                    
Collaborative Agreements disclosures                                    
Potential milestone payments                             $ 70,000,000      
Lilly | Development and Commercialization License | Sales milestones                                    
Collaborative Agreements disclosures                                    
Payments received under collaboration agreement                                 $ 800,000  
Potential milestone payments                             100,000,000      
Lilly | No exercise fee                                    
Collaborative Agreements disclosures                                    
Potential milestone payments                             $ 200,500,000      
Lilly | No exercise fee | Development milestones                                    
Collaborative Agreements disclosures                                    
Number of development and commercialization licenses taken | item                             1      
Potential milestone payments                             $ 30,500,000      
Lilly | Exercise fee | Development milestones                                    
Collaborative Agreements disclosures                                    
Number of development and commercialization licenses taken | item                             2      
Potential milestone payments                             $ 29,000,000